Etidronate, the first nitrogen-free bisphosphonate, has shown efficacy in postmenopausal osteoporosis, but its long-term use in patients with CIO has not been reported. Sato and colleagues ...

The risk of death within 30 days of a diagnosis of stroke was found to rise with increasing doses of the bisphosphonates alendronate and etidronate. By contrast, no increased stroke risk was ...